" class="no-js "lang="en-US"> Emma Sceats - Medtech Alert
Thursday, March 30, 2023
Emma Sceats

Emma Sceats

About Emma Sceats

At Abcam, I lead the global Sales, Service and Business Development teams, focusing on connecting, supporting and collaborating with customers and partners to help deliver scientific breakthroughs.

Prior to Abcam I was CEO of two life sciences tools companies: Isogenica, a contract research organisation specializing in single domain therapeutic antibody discovery, and organ-on-chip pioneer CN Bio Innovations, which built and sold lab equipment and services for in vitro alternatives to animal studies.

My experience is in growing highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing revenue-generating and profitable businesses.

I am an experienced negotiator and contracts specialist, having led complex negotiations to out-license/in-license IP and technologies from pharma and academia, and established research collaborations and consortium agreements with global pharma and leading US/UK/EU universities.

Well-connected executive with pharma, academia, investor, media and government contacts in US, UK and Europe. Inaugural winner of Innovate UK Women in Innovation award (2016).

Educated at leading research institutes (Oxford, MIT).

Related Story

Alamar Biosciences Partners with Abcam to Drive Understanding of the Human Proteome

January 4 2022

Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the […]